Intervention
Aprepitant
ClinicalTrials.gov intervention label
Clinical trials
17 shownEfficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNCT05841849 · 2023-07-01
NOT_YET_RECRUITINGThe Effect of Aprepitant Reducing Postoperative Nausea and VomitingNCT05772676 · 2022-12-01
UNKNOWNMechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3NCT04649229 · 2021-05-27
COMPLETEDAprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus TreatmentNCT02646020 · 2015-12-01
COMPLETEDSafety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin ChemotherapyNCT02445872 · 2015-12-01
UNKNOWNAdding Mirtazapine to Dexamethasone and Aprepitant for Delayed EmesisNCT02336750 · 2014-12-01
COMPLETEDEffect of Chronic ACE and DPP4 Inhibition on Blood PressureNCT02130687 · 2014-06-01
COMPLETEDPharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected SubjectsNCT02154360 · 2014-05-01
COMPLETEDAprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung CancersNCT02161991 · 2014-02-01
COMPLETEDDifferentiating the Effects of Substance P and Beta-endorphinNCT01854177 · 2013-07-01
COMPLETEDA Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung CancerNCT02364804 · 2012-04-01
COMPLETEDIncidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.NCT01298193 · 2011-05-01
COMPLETEDEffects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg DoseNCT01300988 · 2010-12-01
COMPLETEDDecreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric PatientsNCT00956215 · 2010-05-01
COMPLETEDAprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer PatientsNCT00869973 · 2009-09-01
TERMINATEDEffects of Treatment With Aprepitant (Emend®) in HIV Infected IndividualsNCT00428519 · 2007-01-01
COMPLETEDAprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell TransplantNCT00293384 · 2004-10-01
COMPLETEDCommon conditions
Breast Cancer4Chemotherapy-induced Nausea and Vomiting2HIV Infection2Non-small Cell Lung Cancer2Carcinoma, Non-small Cell Lung1Chronic Myeloproliferative Disorders1Chronic Obstructive Pulmonary Disease1Emesis1Gestational Trophoblastic Tumor1Heart Failure1HIV Infections1Hypertension1Leukemia1Lung Cancer1Lymphoma1Multiple Myeloma and Plasma Cell Neoplasm1Myelodysplastic Syndromes1Myelodysplastic/Myeloproliferative Neoplasms1Nausea1Nausea and Vomiting1Nausea and Vomiting, Postoperative1Neuroblastoma1Obesity1Ovarian Cancer1Testicular Germ Cell Tumor1
Leading sponsors
University of Pennsylvania4Barbara Ann Karmanos Cancer Institute1Dartmouth-Hitchcock Medical Center1Fudan University1Hospital General Tlahuac1Hunan Province Tumor Hospital1S. Maria Hospital, Terni1Second Affiliated Hospital, Zhejiang University, School of Medicine1Shiga University1Spanish Breast Cancer Research Group1Sun Yat-sen University1Vanderbilt University1Yale University1Zhejiang University1
Trial status mix
COMPLETED13
UNKNOWN2
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
NA4
PHASE44
PHASE13
PHASE33
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.